Dental Pain Market Holds Immense Opportunities due to Increasing Prevalence of Oral Diseases
The dental pain market, according to industry analysts, is ripe with immediate opportunities for new players and new classes of drugs and therapeutics targeting dental pain management.
The leading causes of dental pain include occlusal trauma, periodontal abscess, pulpitis, apical periodontitis, and alveolar osteitis. Pain can also be caused by non-dental reasons such as maxillary sinusitis, muscle pain, angina pectoris, tumors, and psychological disorders. Treatment modules such as phototherapy, root canal treatment, antifungals, antibiotics such as amoxicillin, penicillin, and cindamycin, fluoride application, and antiseptics are used to address dental pain.
Rising Prevalence of Oral Diseases Worldwide Fueling Dental Pain Market
According to the World Health Organization, almost 100% adults and an estimated 60%-90% of school children have dental cavities. Severe periodontal disease is found in 15%-20% of middle-aged adults. Around 16%-40% of children between the ages of 6 to 12 are affected by dental trauma caused by unsafe schools, unsafe playgrounds, violence, or road accidents.
According to the Centers for Disease Control and Prevention, an estimated 47.2% of adults in above the age of 30 and 70.1% of adults above the age of 65 in the U.S. have some form of periodontal disease. The burden of oral diseases and disorders has resulted in the growth of the global dental pain market.
Strong Efforts by Companies and Research Institutes Boosting Development in the Field of Dental Pain Management and Therapeutics
One of the major factors that has led to remarkable development in the field of dental pain management is the consistent research efforts and clinical trials by major companies and top institutes and government bodies.
Obtain the Forthcoming Market Trends of Dental Pain Treatment at: http://bit.ly/2fwih4q
Jean Brown Research, Eli Lilly and Company, C. H. Boehringer Sohn AG & Co. KG, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bayer AG, Amgen Inc., Premier Research Group Limited, and GlaxoSmithKline Plc are some of the leading companies involved in clinical trials dealing with dental pain management.
On the other hand, some of the top universities and government associations working on clinical trials on dental pain therapeutics are Islamic Azad University, Khorasgan Branch, Isfahan University of Medical Sciences, Nippon Dental University School of Life Dentistry, Kermanshah University of Medical Sciences, Hamedan University of Medical Sciences, Zahedan University of Medical Sciences, Babol University of Medical Sciences, Shiraz University of Medical Sciences, The University of Hong Kong, and Islamic Azad University, Tehran.
Other factors that contribute towards the growth of the dental pain market include higher purchasing power, supportive government initiatives, extensive reforms, rising demand for restorative dental treatment, technological advancements in oral health and dental surgery, surging demand for improved and painless diagnostics, availability of specialized resources, and better reimbursement services.
Asia Pacific has been identified as one of the most lucrative markets for dental pain management and therapeutics, given the rising population with oral health problems and increase in disposable income.
The pain management market, on the whole, is admittedly a mature market, which allows players to come up with new therapies that are more efficacious than existing medications.